Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma (Q73904603)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

title

Four-year biochemical outcome after radioimmunoguided transperineal brachytherapy for patients with prostate adenocarcinoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

main subject

prostate adenocarcinoma

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Sam Beddar

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

author name string

Rodney J Ellis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Amy Vertocnik

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Edward Kim

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Hang Zhou

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Benjamin Young

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Bruce Sodee

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Valdir Colussi

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

John P Spirnak

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Kurt H Dinchman

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Martin Resnick

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

Timothy J Kinsella

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

English

0 references

publication date

1 October 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

International Journal of Radiation Oncology Biology Physics

7 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

57

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

362-370

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Palladium-103 brachytherapy for prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Radioimmunoguided imaging of prostate cancer foci with histopathological correlation

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Prostate cancer and prostate bed SPECT imaging with ProstaScint: semiquantitative correlation with prostatic biopsy results

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Feasibility and acute toxicities of radioimmunoguided prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Risk group stratification in patients undergoing permanent (125)I prostate brachytherapy as monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Five-year biochemical outcome following permanent interstitial brachytherapy for clinical T1-T3 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Biochemical outcome for hormone-naïve intermediate-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external beam radiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

The effect of prognostic factors on therapeutic outcome following transperineal prostate brachytherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0360-3016%2803%2900588-1

7 January 2021

10.1016/S0360-3016(03)00588-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12957246%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference